Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
$425K Buy
3,788
+873
+30% +$93K ﹤0.01% 1790
2019
Q3
$281K Sell
2,915
-15
-0.5% -$1.41K ﹤0.01% 2060
2019
Q2
$251K Buy
2,930
+1,179
+67% +$96.9K ﹤0.01% 2130
2019
Q1
$146K Sell
1,751
-558
-24% -$40.5K ﹤0.01% 2541
2018
Q4
$148K Buy
2,309
+59
+3% +$4.04K ﹤0.01% 2322
2018
Q3
$178K Buy
2,250
+1,620
+257% +$125K ﹤0.01% 2264
2018
Q2
$46K Hold
630
﹤0.01% 3153
2018
Q1
$40K Sell
630
-100
-14% -$5.97K ﹤0.01% 3242
2017
Q4
$38K Hold
730
﹤0.01% 3274
2017
Q3
$39K Hold
730
﹤0.01% 3112
2017
Q2
$38K Sell
730
-50
-6% -$2.47K ﹤0.01% 3026
2017
Q1
$34K Buy
780
+100
+15% +$4.3K ﹤0.01% 2995
2016
Q4
$30K Buy
680
+380
+127% +$16.1K ﹤0.01% 2968
2016
Q3
$12K Buy
+300
New +$12.7K ﹤0.01% 3440

Other funds holding CNMD

Advisor Group's CNMD Position: Q4 2019 in Review

Advisor Group increased its CONMED (CNMD) stake by 30% in Q4 2019, buying an estimated $93K and bringing the position to 3,788 shares worth $425K. The position accounts for ﹤0.01% of the portfolio, ranked #1790.

Advisor Group first reported a position in CNMD in Q3 2016 and has held it in 14 quarters since. 264 funds tracked by Wall St. Rank hold CNMD as of Q4 2019.

  • Advisor Group held 3,788 shares of CONMED worth $425K as of Q4 2019.
  • Advisor Group bought 873 CONMED shares in Q4 2019, an estimated $93K.
  • CONMED made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #1790 holding.
  • Advisor Group first reported a position in CONMED in Q3 2016 and has held it in 14 quarters since.
  • 264 funds tracked by Wall St. Rank held CONMED as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.